{"title": "KAVA: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews", "author": null, "url": "https://www.webmd.com/vitamins/ai/ingredientmono-872/kava", "hostname": "webmd.com", "description": "Learn more about KAVA uses, effectiveness, possible side effects, interactions, dosage, user ratings and products that contain KAVA.", "sitename": "webmd.com", "date": "2005-01-01", "cleaned_text": "R. J. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. Phytother Res 2001;15(7):646-647. View abstract. Boonen, G., Ferger, B., Kuschinsky, K., and Haberlein, H. effects the (+)-dihydromethysticin and kavain on dopamine, 3,4-dihydroxyphenylacetic acid, 5- hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med 1998;64(6):507-510. View abstract. Buckley, J. P., Furgiuele, A. R., and O'Hara, M. J. Pharmacology of kava. Ethnopharm Search Psych Drugs 1967;1:141-151. Cairney, S., Clough, A. R., Maruff, P., Collie, A., Currie, B. J., and Currie, J. Saccade and cognitive function in chronic kava users. Neuropsychopharmacology 2003;28(2):389-396. View abstract. Cairney, S., Maruff, P., and Clough, A. R. The neurobehavioural effects of kava. Aust.N.Z.J Psychiatry 2002;36(5):657-662. View abstract. Cawte, J. Parameters of kava used as a challenge to alcohol. Aust.N.Z.J Psychiatry 1986;20(1):70-76. View abstract. Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Kava-containing dietary supplements may be associated with severe liver injury (document issued March 25, 2002). Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Letter to health care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury (document issued March 25, 2002), contact information for FDA Medwatch program: 1-800-332-1088. Chanwai, L. G. Kava toxicity. Christl, S. U., Seifert, A., and Seeler, D. Toxic hepatitis after consumption of traditional kava preparation. J.Travel.Med. 2009;16(1):55-56. View abstract. De Leo, V, La Marca, A., Lanzetta, D., Palazzi, S., Torricelli, M., Facchini, C., and Morgante, G. [Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmenopause anxiety]. Minerva Ginecol. 2000;52(6):263-267. View abstract. Duffield, A. M., Jamieson, D. D., Lidgard, R. O., Duffield, P. H., and Bourne, D. J. Identification of some human urinary metabolites of the intoxicating beverage kava. J Chromatogr. 7-28-1989;475:273-281. View abstract. Emser W and Bartylla K. Improvement of sleep quality. Effect of kava extract WS 1490 on the sleep pattern in healthy subjects. Neurologie/Psychiatrie 1991;5(11):636-642. Ernst, E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine 2006;13(3):205-208. View abstract. Faustino, T. T., Almeida, R. B., and Andreatini, R. [Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies]. Rev Bras.Psiquiatr. 2010;32(4):429-436. View abstract. Feltenstein, M. W., C., Ganzera, M., Ranjith, H., Dharmaratne, W., Nanayakkara, N. P., Khan, I. A., and Sufka, K. J. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. Phytother Res 2003;17(3):210-216. View abstract. Folmer, M., and Diederich, M. Inhibition of TNFalpha-induced activation of kava (Piper methysticum) derivatives. Biochem Pharmacol 4-14-2006;71(8):1206-1218. View abstract. Foo, H. and Lemon, J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev. 1997;16(2):147-155. View abstract. Food and Drug Administration. Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury. FDA Center for Food Safety and Nutrition. 2002;1. Furgiuele AR, Kinnard WJ, Aceto MD, and et al. Central activity of aqueous extracts of Piper methysticum (kava). J Pharm Sci 1965;54:247-252. Garrett, K. M., Basmadjian, G., Khan, I. A., Schaneberg, B. T., and Seale, T. W. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacology (Berl) 2003;170(1):33-41. View abstract. Geller, S. E. and Studee, L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause. 2007;14(3 Pt 1):541-549. View abstract. Gessner B and Cnota P. Extract of the kava-kava rhizome in comparison with diazepam and placebo. Z Phytother 1994;15(1):30-37. Gleitz J, Gottner N, Ameri inhibits non-stereospecifically veratridine-activated Na Gleitz, J., Beile, A., and Peters, T. inhibits the veratridine- and KCl-induced increase Ameri, A., and Peters, T. Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur.J Pharmacol 11-7-1996;315(1):89-97. Kava-induced urticaria. J Am Acad Dermatol 2005;53(5):906. View abstract. HAMILTON, M. The assessment of anxiety states by rating. Br.J.Med.Psychol. 1959;32(1):50-55. View abstract. Holm, E., Staedt, U., Behne, F., A., and Mennicke, I. [The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness- rhythm in animals]. Arzneimittelforschung. 1991;41(7):673-683. View abstract. Humberston, C. L., Akhtar, J., and Krenzelok, E. P. Acute hepatitis induced by kava kava. J Toxicol.Clin Toxicol. 2003;41(2):109-113. View abstract. Izzo AA and Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61(15):2163-2175. Jappe, U., Franke, I., Reinhold, D., and Gollnick, H. P. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol. 1998;38(1):104-106. View abstract. Johnson D, Frauendorf A, Stecker K, and et al. Neurophysiological active profile and tolerance of kava extract WS 1490, A pilot study with randomized evaluation. TW Neurolgie Psychiatrie 1991;5(6):349-354. Keller F and Klohs M. A review of the chemistry and pharmacology of the constituents of Piper methysticum. Lloydia 1963;26:1-15. Kelley, K. W. and Carroll, D. G. Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women. J.Am.Pharm.Assoc.(2003.) 2010;50(5):e106-e115. View abstract. Kinzler, E., Kromer, J., and Lehmann, E. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. Arzneimittelforschung. 1991;41(6):584-588. View abstract. Lakhan, S. E. and Vieira, K. F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010;9:42. View abstract. Langosch, J. M., Normann, C., Schirrmacher, K., Berger, M., and Walden, J. The influence of (+/-)-kavain on population spikes and long-term potentiation in guinea pig hippocampal slices. Comp Biochem.Physiol A Mol.Integr.Physiol 1998;120(3):545-549. View abstract. Sarris, Scholey, A. Neurocognitive of kava (Piper methysticum): a systematic review. Hum.Psychopharmacol. 2011;26(2):102-111. View abstract. Lehmann E, Kinzler E, and Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - a double-blind placebo-controlled study of weeks Phytomedicine 1996;3(2):113-119. Klieser, E., Klimke, A., Krach, H., and Spatz, R. The efficacy of Cavain in patients suffering from anxiety. Pharmacopsychiatry 1989;22(6):258-262. View abstract. Leung, N. Acute urinary retention secondary to kava ingestion. Emerg Med Australas 2004;16(1):94. D. and Pitule-Schodel, H. [D,L-kavain in comparison with oxazepam in anxiety disorders. A double- blind study of clinical effectiveness]. Fortschr.Med. 1-20-1990;108(2):49-53. View abstract. Ma, Y., Sachdeva, K., Liu, J., Ford, M., Yang, D., Khan, I. A., Chichester, C. O., and Yan, B. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked induction Dispos 2004;32(11):1317-1324. Magura, E. M. Gleitz, J., Peters, T., and Krishtal, O. A. Kava extract ingredients, (+)-methysticin and Malsch U and Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharm 2001;157(3):277-283. Matthias, A., Blanchfield, J. T., Penman, K. G., Bone, K. M., Toth, I., and Lehmann, R. P. Permeability studies of Kavalactones Clin Pharm 2007;32(3):233-239. D., Kohrman, M., Gooneratne, N., Aguillard, R. Townsend, Claman, D., Hoban, T., and Mahowald, M. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin.Sleep Med 4-15-2005;1(2):173-187. View abstract. Mittmann, U., Schmidt, M., Schmidt, T., and Lehmann, E. [Treatment of perioperative anxiety in suspected breast carcinoma with a phytogenic tranquilizer]. Zentralbl.Gynakol. 2000;122(11):561-565. View abstract. Pfeiffer, C. C., Murphree, H. B., and Goldstein, L. Effect of kava in normal subjects and patients. Psychopharmacol Bull 1967;4(3):12. View abstract. Pittler, M. H. and Ernst, E. Kava extract for treating anxiety. Cochrane Database.Syst Rev 2002;(2):CD003383. View abstract. Prescott, J., Jamieson, D., Emdur, N., and Duffield, P. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alcohol Rev. 1993;12(1):49-57. View abstract. Rasmussen, A. K., Scheline, R. R., Solheim, E., and Hansel, R. Metabolism of some kava pyrones in the rat. Xenobiotica 1979;9(1):1-16. View abstract. Russell P, Bakker D, and Singh N. The effects of kava on alerting and speed of access of information from long-term memory. Bull Psychonom Soc 1987;25:236-237. Saletu B, Gr\u00fcnberger J, Linzmayer L, and et al. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative. Hum Psychopharm 1989;4:169-190. Sarris, J. and Kavanagh, D. J. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J.Altern.Complement Med. 2009;15(8):827-836. View abstract. Sarris, J., Kavanagh, D. J., Adams, J., Bone, K., and Byrne, G. Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum. Complement Ther.Med. 2009;17(3):176-178. View abstract. Sarris, J., Kavanagh, D. J., Deed, G., and Bone, K. M. St. John's wort and Kava in treating major depressive disorder with anxiety: a double-blind Sarris, J., Laporte, E., and Schweitzer, I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust.N.Z.J.Psychiatry 2011;45(1):27-35. View abstract. Sarris, J., Panossian, A., Schweitzer, I., Stough, C., and Scholey, A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur.Neuropsychopharmacol. 2011;21(12):841-860. View abstract. Scherer, J. Kava-kava extract in anxiety disorders: an outpatient observational study. Adv.Ther. 1998;15(4):261-269. View abstract. Schmidt, M. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. J Altern Med 2003;9(2):183-187. View abstract. Siegers CP, Honold E, Krall B, and et al. Results of the drug monitoring L 1090 with Laitan capsules. Arztl Forsch 1992;39:7-11. Singh Y and Blumenthal M. Kava: an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. HerbalGram Seitz, G., Seitz, H. K., and Schuppan, D. induced by Kava (Piper methysticum rhizoma). J Hepatol. 2003;39(1):62-67. View abstract. Thompson, R., Ruch, W., and Hasenohrl, R. U. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Hum.Psychopharmacol. 2004;19(4):243-250. View abstract. van der Watt, G., Laugharne, J., and Janca, A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr.Opin.Psychiatry 2008;21(1):37-42. View abstract. Walden J, von Wegerer J, Winter U, and et al. Actions of kavain and dihydromethysticin on ipsapirone-induced field potential changes in the hippocampus. Human Psychopharm 1997;12:265-270. Watkins, L. L., Connor, K. M., and Davidson, J. R. Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. J Psychopharmacol. 2001;15(4):283-286. View abstract. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001;15:549-551. View abstract. Whitton, P. A., Lau, A., Salisbury, A., Whitehouse, J., and Evans, C. S. Kava lactones and the kava-kava controversy. Phytochemistry 2003;64(3):673-679. View abstract. H, Kapoula O, Lehrl S, and et al. [Treatment of patients suffering from anxiety- double-blind study: kava special extract versus benzodiazepines]. Z Allg Med 1993;69:271-277. Zhou, S. F., Xue, C. C., Yu, X. Q., and Wang, G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 2007;8(6):526-553. View abstract. Anon. Hepatic toxicity possibly with kava-containing products-United States, Germany, Switzerland, 1999-2002. MMWR 2002;1:1065-1067.. View abstract. Aporosa AS, Atkins M, Brunton R. Kava drinking in traditional settings: towards understanding effects on cognitive function. Hum Psychopharmacol. 2020;35(2):e2725. View abstract. Aporosa S', Ballard H, Pandey R, McCarthy MJ. The impact of traditional kava (Piper methysticum) use on cognition: Implications for driver fitness. J Ethnopharmacol 2022;291:115080. View abstract. Asher GN, Corbett AH, Hawke RL. Common Herbal Dietary Supplement-Drug Interactions. Am Fam Physician. 2017;96(2):101-107. View abstract. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Neuropsychopharmacol FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 2002;70:2581-97. View abstract. Bodkin R, Schneider S, Rekkerth D, et al. Rhabdomyolysis associated with kava ingestion. Am J Emerg Med 2012;30:635.el-3. View abstract. Boerner RJ, Sommer H, Berger W, et al. Kava-Kava extract LI 150 is as effective as opipramol in generalised anxiety R, Haberlein H. Evidence for specific interactions between kavain and human cortical neurons monitored by fluorescence correlation spectroscopy. Med 2000;66:7-10. View abstract. Cagnacci A, Arangino S, Renzi A, et al. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas 2003;44:103-9. View abstract. Cairney S, Maruff P, Clough AR, et al. Saccade and cognitive impairment associated with kava intoxication. Hum Psychopharmacol 2003;18:525-33. View abstract. Connor KM, Davidson JR. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int Clin.Psychopharmacol 2002;17:185-8. View abstract. Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006;21:249-53. View abstract. Consultation letter MLX 286: Proposals to prohibit the herbal ingredient Kava-Kava (Piper methysticum) in unlicensed medicines. Medicines Control Agency, United Kingdom, July 19, 2002. Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 2002;16:23-7.View abstract. Davies LP, Drew CA, Duffield P, et al. Kava Pyrones and Resin: Studies on GABA-A, Brain. View Denham A, McIntyre Whitehouse Kava--the unfolding story: report on a work-in-progress. J Altern Complement Med 2002;8:237-263.. View abstract. Donadio V, Bonsi P, Zele I, et al. Myoglobinuria after ingestion of extracts of Ginkgo J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001;322:139. View abstract. Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999. Garner LF, Klinger JD. Some effects caused by the beverage kava. J Ethnopharmacol 1985;13:307-311.. View abstract. Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract Kava treatment in patients with anxiety. Phytother Res 2004;18:297-300. View abstract. Gleitz J, Beile A, Wilkens et al. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets. Planta Med 1997;63:27-30. View abstract. Gow PJ, Connelly NJ, Hill RL, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003;178:442-3. View abstract. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava abstract. BJ, Swain al. Clinical assessement of CYP2D6-mediated herb-drug interactions View abstract. Hannam S, Romani L, Tuicakau M, J Whitfeld M. Kava Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 1994;27:224-30. View abstract. Huynh JC, Asgari MM, Moore MM. Sebotropic eruption associated with of oral kava kava supplement. Clin Exp Dermatol 2014;39(7):816-8. View abstract. Jacobs S, Tice JA, et al. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore) 2005;84:197-207. View abstract. Jorm, A. F., Christensen, H., Griffiths, K. M., Parslow, R. A., Rodgers, B., and Blewitt, K. A. Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust 2004;181(7 Suppl):S29-S46. View abstract. Jussofie A, Schmiz A, Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994;116:469-74. View abstract. Ketola RA, Viinam\u00e4ki J, Rasanen I, A, Goebeler S. Fatal kavalactone intoxication by suicidal intravenous injection. Forensic Sci Int 2015;249:e7-e11. View abstract. Kuchta K, Schmidt M, Nahrstedt A. German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics. Planta Med. 2015;81(18):1647-53. View abstract. Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - a double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996;3:113-9. View abstract. Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord 2004;78:101-10. View abstract. Li XZ, Ramzan I. Role of ethanol in kava hepatotoxicity. Phytother 2010;24:475-80. View abstract. Liver Toxicity With Kava. Pharmacist's Letter/Prescriber's Letter. January 2001. Logan JL, Ahmed J. Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: View abstract. Malsch U, Kieser M. Efficacy of kava-kava in the treatment non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl) 2001;157:277-83. View abstract. Mathews JD, Riley MD, Fejo L, et al. Effects of heavy usage of kava on physical health: Summary of a pilot survey in an aboriginal community. Med J Aust 1988;148:548-55. View abstract. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome kava 2002;30:1153-7. View abstract. E, Taboada Sanchez al. Life-threatening parkinsonism induced by kava-kava. Mov Disord 2002;17:195-6. View abstract. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Int Med 1998;158:2200-11.. View abstract. Moulds RF, Malani J. Kava: herbal panacea abstract. Munte Matzke M, J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993;27:46-53. View abstract. Norton SA, Ruze P. Ostermayer D. News: Kava, Popular as Alcohol Alternative, May Cause Toxicity. Emerg Med News. 2016;38(1B). Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000;20:84-9. View abstract. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003;(1):CD003383. View abstract. Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. 2nd ed. Edinburgh:Churchill Livingstone, 1999. Raju Kanumuri SR, Mamallapalli J, Nelson R, et al. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers. J Ethnopharmacol a Z J Psychiatry 2019:4867419891246. View abstract. Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover using an Psychopharmacology 2009;205:399-407. View abstract. Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C, Schweitzer I. Kava in the treatment of generalized anxiety disorder: a double-blind, placebo-controlled C, Teschke Wahid ZT, Bousman CA, Murray G, Savage KM, Mouatt P, Ng C, Schweitzer I. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res 2013;27(11):1723-8. View abstract. Schelosky L, Raffaup C, Jendroska Poewe Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995;58:639-40. View abstract. Schmidt M. German Court Ruling Reverses Kava Ban; German Regulatory Authority Appeals Decision. HerbalEGram. Phytomedicine Seitz U, kava pyrones. Planta Med 1997;63:548-549.. View abstract. YN, Blumenthal M. Kava an overview. HerbalGram 1997;39:33-44, 46-55. Singh YN. Effects of on neuromuscular transmission and muscle contractility. J Ethnopharmacol 1983;7:267-76.. View abstract. Singh YN. Kava: an overview. J Ethnopharmacol 1992;37:13-45. View abstract. Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract. 2018;33:107-117. View abstract. Spillane PK, et al. Neurological manifestations of kava intoxication. Med J Aust 1997;167:172-3. View abstract. Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000;59:420-2. View abstract. Strahl S, Ehret V, Dahm Wochenschr 1998;123:1410-4. View abstract. Swensen JN. Man convicted of driving under the influence of kava. Salt Lake City, UT: Deseret News, 1996. Teschke R, Gaus W, Loew safety hepatotoxicity. Phytomedicine 2003;10:440-6. View abstract. Teschke R, Lebot V. Proposal for a Kava Quality Standardization Code. Food Chem Toxicol 2011;49(10):2503-16. View abstract. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Pharmacol 2012;73(2):170-4. View abstract. Teschke R. Kava hepatotoxicity: pathogenetic prospective considerations. Liver Int 2010;30(9):1270-9. View abstract. Toohey TP, Lu BY, Wada C. Toxic effects of psychotropics related to possible p450 enzyme inhibition by kava:report of 2 cases. Prim Disord 2013;15(5). View abstract. Pharmacopsychiatry 1998;31:187-92. View abstract. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom abstract. Volz HP, Kieser Pharmacopsychiatry 1997;30:1-5. View abstract. Wainiqolo I, Kafoa B, Kool B, et al. Driving following kava use and road traffic injuries: a population-based case-control study in Fiji (TRIP 14). PLoS One 2016;11(3):e0149719. View abstract. Wainiqolo I, Kool B, Nosa V, Ameratunga S. Is driving under the influence of kava associated with motor vehicle crashes? A systematic review of the epidemiological literature. Aust N Z J Public Health 2015;39(5):495-9. View abstract. Wang Y, Narayanapillai SC, Tessier KM, et al. The impact of one-week dietary supplementation with kava on biomarkers of tobacco use and nitrosamine-based carcinogenesis risk among active smokers. Cancer Prev Res (Phila). 2020;13(5):483-92. View abstract. Warnecke G. [Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness tolerance of Kava extract WS 1490]. Fortschr Med 1991;109:119-22. View abstract. Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. inhibit Drug Metab Dispos 2005;33:1580-3. abstract. Welihinda J, et al. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986;17:277-82. View abstract. Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol 2001;16:353-6. View abstract. Witte S, Loew D, Gaus W. of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Res 2005;19:183-8. View abstract. Woelk H, Kapoula O, Lehrl et [Comparison of kava special extract WS 1490 and Z Allg Med 1993;69:271-7. Wooltorton E. Herbal kava: reports of liver toxicity. CMAJ 2002;166:777. View abstract. Wu D, Yu L, Nair MG, et al. Cyclooxygenase enzyme inhibitory compounds kava) roots. Phytomedicine 2002;9:41-7. View abstract. "}